<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Microbiology">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Microbiology</JournalTitle>
      <Issn>2008-3289</Issn>
      <Volume>18</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="epublish">
        <Year>2026</Year>
        <Month>10</Month>
        <Day>05</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Ceftazidime-avibactam activity against urinary carbapenem resistance Escherichia coli and Klebsiella pneumoniae isolates</title>
    <FirstPage>670</FirstPage>
    <LastPage>676</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Siavosh</FirstName>
        <LastName>Salmanzadeh-Ahrabi</LastName>
        <affiliation locale="en_US">Women Research Center, Alzahra University, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Farzaneh</FirstName>
        <LastName>Salehinejad</LastName>
        <affiliation locale="en_US">Department of Biotechnology, Faculty of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Masoud</FirstName>
        <LastName>Sokhanvar-Mahani</LastName>
        <affiliation locale="en_US">Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2026</Year>
        <Month>02</Month>
        <Day>20</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2026</Year>
        <Month>09</Month>
        <Day>20</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background and Objectives: Urinary tract infections (UTIs) are among the most prevalent bacterial infections in women, with Escherichia coli and Klebsiella pneumoniae as leading causative pathogens. The emergence of multidrug-resistant (MDR) and carbapenem-resistant strains poses a significant therapeutic challenge. Ceftazidime&#x2013;avibactam (CZA) has shown activity against &#x3B2;-lactamase-producing Gram-negative bacteria; however, data on its activity against urinary carbapenem-resistant isolates remain limited. This study aimed to determine CZA activity against urinary carbapenem-resistant E. coli and K. pneumoniae isolates.
Materials and Methods: In this cross-sectional study, antimicrobial susceptibility testing was performed using the disk diffusion method according to CLSI guidelines. The tested antibiotics included carbapenems, third-generation cephalosporins, aminoglycosides, levofloxacin, fosfomycin, and CZA. Extended-spectrum &#x3B2;-lactamase (ESBL) production was assessed using the combined-disk method.
Results: A total of 76 previously collected urinary bacterial isolates, including 44 (57.9%) E. coli and 32 (42.1%) K. pneumoniae isolates were included in this study. Carbapenem resistance was detected in 25.0% (11/44) of E. coli and 28.1% (9/32) of K. pneumoniae isolates. ESBL production was observed in 36.4% and 37.5%, respectively. Overall, CZA susceptibility was 68.2% for E. coli and 68.7% for K. pneumoniae, decreasing to 27.3% and 22.2%, respectively, among carbapenem-resistant isolates. Overall, 25.0% of carbapenem-resistant isolates remained susceptible to CZA. Fosfomycin susceptibility was 81.8% and 46.9% among E. coli and K. pneumoniae, respectively.
Conclusion: CZA demonstrated substantial in vitro activity against urinary E. coli and K. pneumoniae isolates; however, its activity was markedly reduced among carbapenem-resistant strains. These findings highlight the importance of susceptibility-guided use of CZA and continued surveillance of antimicrobial resistance.</abstract>
    <web_url>https://ijm.tums.ac.ir/index.php/ijm/article/view/6079</web_url>
    <pdf_url>https://ijm.tums.ac.ir/index.php/ijm/article/download/6079/1927</pdf_url>
  </Article>
</Articles>
